Scope of Things Podcast: Daphne Smyth on the Chinese Drug Development Market Expansion

China is rapidly becoming one of the most influential forces in global drug development—but bringing innovative therapies to patients worldwide requires more than scientific progress. It requires a regulatory strategy built for global success.

In the latest Scope of Things podcast from SCOPE Summit, Veristat's Daphne Smyth, VP of Global Regulatory Affairs, discusses how China's biopharma ecosystem is evolving, why more companies are looking beyond domestic approvals, and what sponsors need to consider when planning development programs for the U.S., Europe, and other international markets.

In the conversation, Daphne explores:

• Why China has become a global engine for biopharma innovation
• The regulatory considerations that shape international development strategies
• Common challenges companies face when bringing Chinese-developed therapies to global markets
• Why planning for global regulatory expectations early can accelerate success